Medicaid program; time limitation on record keeping requirements under the drug rebate program. Interim final rule with comment period
Related Experiment Video
Updated: Aug 26, 2026

Assessment of Ultrasonic Vocalizations During Drug Self-administration in Rats
Published on: July 22, 2010
Abstract:
On August 29, 2003, we published a final rule with comment period in the Federal Register that finalized two specific provisions: it established new 3-year recordkeeping requirements for drug manufacturers under the Medicaid drug rebate program and set a 3-year time limitation during which manufacturers must report changes to average manufacturer price and best price for purposes of reporting data to us. In addition, it announced the pressing need for codification of fundamental recordkeeping requirements. On September 26, 2003, we issued a correction notice to change the effective date of the August 29, 2003 rule from October 1, 2003 to January 1, 2004. In this interim final rule with comment period, we are removing the 3-year recordkeeping requirements, replacing them with 10-year recordkeeping requirements on a temporary basis, and soliciting comments on the 10-year requirements. Manufacturers must retain records beyond the 10-year period if the records are the subject of an audit or a government investigation of which the manufacturer is aware. These provisions contain a sunset date with respect to the record retention requirements to ensure that we reexamine whether the retention rule remain necessary and effective. This interim final rule with comment period also responds to public comments on the August 29, 2003 final rule with comment period that pertain to the 3-year recordkeeping requirement at Sec. 447.534(h).
Related Concept Videos
Drug Regulation
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Dosing: Geriatric Patients